Carolina A Isnardi, Cecilia Pisoni, Micaela Cosatti, Karen Roberts, Belén M Virasoro, Jennifer Kreimer, Cristina Echeverría, María E D'Angelo, Dora Pereira, Ingrid Petkovic, Yohana Soledad Tissera, María Á Correa, Gustavo Rodríguez Gil, Rosana Quintana, Karina Cogo, Carla Alonso, Nora Kogan, Ana L Toledo, M Agustina Alfaro, Romina Nieto, Lucila García, Alejandra Rollano Perasso, María E Debernardi, Zaida Troyano, Ingrid Strusberg, Guillermo J Pons-Estel, Emilce E Schneeberger
{"title":"阿根廷风湿病和牛皮癣患者接种SARS-CoV-2疫苗的不良反应","authors":"Carolina A Isnardi, Cecilia Pisoni, Micaela Cosatti, Karen Roberts, Belén M Virasoro, Jennifer Kreimer, Cristina Echeverría, María E D'Angelo, Dora Pereira, Ingrid Petkovic, Yohana Soledad Tissera, María Á Correa, Gustavo Rodríguez Gil, Rosana Quintana, Karina Cogo, Carla Alonso, Nora Kogan, Ana L Toledo, M Agustina Alfaro, Romina Nieto, Lucila García, Alejandra Rollano Perasso, María E Debernardi, Zaida Troyano, Ingrid Strusberg, Guillermo J Pons-Estel, Emilce E Schneeberger","doi":"10.1097/RHU.0000000000002251","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/objective: </strong>Patients with systemic rheumatic diseases were initially excluded from coronavirus disease 2019 (COVID-19) vaccine trials. Real-world data on vaccine safety in this population remain limited, particularly for non-mRNA vaccines. The aim of this study was to evaluate the safety of COVID-19 vaccines in patients with rheumatic diseases and/or psoriasis.</p><p><strong>Methods: </strong>A longitudinal observational study including vaccinated patients ≥18 years old with rheumatic diseases and/or psoriasis vaccinated against COVID-19 was conducted. Adverse events (AEs) and disease flares were documented. Multivariable logistic regression analysis identified factors associated with AEs.</p><p><strong>Results: </strong>Among 2160 patients with rheumatic diseases and/or psoriasis vaccinated against COVID-19 (3988 doses), 29.6% reported at least 1 AE, mostly mild/moderate flu-like symptoms and local hypersensitivity. AE incidence was highest for mRNA-1273 (316.7/1000 doses) and lowest for BBIBP-CorV (95.4/1000). Heterologous regimens and ChAdOx1 nCoV-19 as first dose were associated with increased AE risk, whereas BBIBP-CorV showed the opposite effect. Disease flares occurred in 2.5% of patients, predominantly arthritis and arthralgia, without association with any specific vaccines.</p><p><strong>Conclusion: </strong>COVID-19 vaccines were generally well tolerated, with AE rates comparable to the general population. Heterologous regimens and vector-based and mRNA vaccines had higher AE incidence. These findings provide valuable safety data on vaccines used in Argentina and the region.</p>","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adverse Effects Related to SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases and Psoriasis From Argentina.\",\"authors\":\"Carolina A Isnardi, Cecilia Pisoni, Micaela Cosatti, Karen Roberts, Belén M Virasoro, Jennifer Kreimer, Cristina Echeverría, María E D'Angelo, Dora Pereira, Ingrid Petkovic, Yohana Soledad Tissera, María Á Correa, Gustavo Rodríguez Gil, Rosana Quintana, Karina Cogo, Carla Alonso, Nora Kogan, Ana L Toledo, M Agustina Alfaro, Romina Nieto, Lucila García, Alejandra Rollano Perasso, María E Debernardi, Zaida Troyano, Ingrid Strusberg, Guillermo J Pons-Estel, Emilce E Schneeberger\",\"doi\":\"10.1097/RHU.0000000000002251\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/objective: </strong>Patients with systemic rheumatic diseases were initially excluded from coronavirus disease 2019 (COVID-19) vaccine trials. Real-world data on vaccine safety in this population remain limited, particularly for non-mRNA vaccines. The aim of this study was to evaluate the safety of COVID-19 vaccines in patients with rheumatic diseases and/or psoriasis.</p><p><strong>Methods: </strong>A longitudinal observational study including vaccinated patients ≥18 years old with rheumatic diseases and/or psoriasis vaccinated against COVID-19 was conducted. Adverse events (AEs) and disease flares were documented. Multivariable logistic regression analysis identified factors associated with AEs.</p><p><strong>Results: </strong>Among 2160 patients with rheumatic diseases and/or psoriasis vaccinated against COVID-19 (3988 doses), 29.6% reported at least 1 AE, mostly mild/moderate flu-like symptoms and local hypersensitivity. AE incidence was highest for mRNA-1273 (316.7/1000 doses) and lowest for BBIBP-CorV (95.4/1000). Heterologous regimens and ChAdOx1 nCoV-19 as first dose were associated with increased AE risk, whereas BBIBP-CorV showed the opposite effect. Disease flares occurred in 2.5% of patients, predominantly arthritis and arthralgia, without association with any specific vaccines.</p><p><strong>Conclusion: </strong>COVID-19 vaccines were generally well tolerated, with AE rates comparable to the general population. Heterologous regimens and vector-based and mRNA vaccines had higher AE incidence. These findings provide valuable safety data on vaccines used in Argentina and the region.</p>\",\"PeriodicalId\":520664,\"journal\":{\"name\":\"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/RHU.0000000000002251\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/RHU.0000000000002251","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Adverse Effects Related to SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases and Psoriasis From Argentina.
Background/objective: Patients with systemic rheumatic diseases were initially excluded from coronavirus disease 2019 (COVID-19) vaccine trials. Real-world data on vaccine safety in this population remain limited, particularly for non-mRNA vaccines. The aim of this study was to evaluate the safety of COVID-19 vaccines in patients with rheumatic diseases and/or psoriasis.
Methods: A longitudinal observational study including vaccinated patients ≥18 years old with rheumatic diseases and/or psoriasis vaccinated against COVID-19 was conducted. Adverse events (AEs) and disease flares were documented. Multivariable logistic regression analysis identified factors associated with AEs.
Results: Among 2160 patients with rheumatic diseases and/or psoriasis vaccinated against COVID-19 (3988 doses), 29.6% reported at least 1 AE, mostly mild/moderate flu-like symptoms and local hypersensitivity. AE incidence was highest for mRNA-1273 (316.7/1000 doses) and lowest for BBIBP-CorV (95.4/1000). Heterologous regimens and ChAdOx1 nCoV-19 as first dose were associated with increased AE risk, whereas BBIBP-CorV showed the opposite effect. Disease flares occurred in 2.5% of patients, predominantly arthritis and arthralgia, without association with any specific vaccines.
Conclusion: COVID-19 vaccines were generally well tolerated, with AE rates comparable to the general population. Heterologous regimens and vector-based and mRNA vaccines had higher AE incidence. These findings provide valuable safety data on vaccines used in Argentina and the region.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
